Literature DB >> 1568221

Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas.

O I Olopade1, R B Jenkins, D T Ransom, K Malik, H Pomykala, T Nobori, J M Cowan, J D Rowley, M O Diaz.   

Abstract

Previous studies have suggested that structural abnormalities involving the short arm of chromosome 9 are frequently associated with gliomas. The alpha-, beta-, and omega-interferon (IFNA, IFNB1, and IFNW, respectively) and the methylthioadenosine phosphorylase (MTAP) genes have been mapped to the short arm of chromosome 9, band p22. Homozygous deletions of these genes have been reported in many leukemia- and glioma-derived cell lines. In this report, we present a detailed analysis of partial and complete homozygous or hemizygous deletions of DNA sequences on 9p in human cell lines and primary tumor samples of glioma patients. Ten of 15 (67%) glioma-derived cell lines had hemizygous or homozygous deletion of IFN genes or rearrangement of sequences around these genes, while 13 of 35 (37%) primary glioma tumor samples had hemizygous (8 tumors) or homozygous (5 tumors) deletion of the IFN genes. The shortest region of overlap of these deletions maps in the interval between the centromeric end of the IFN gene cluster and the MTAP gene. In the cell lines and primary tumors examined, these gross genomic alterations were seen only in association with high grade or recurrent gliomas. Our observations confirm that loss of DNA sequences on 9p, particularly the IFN genes, occurs at a significant frequency in gliomas, and may represent an important step in the progression of these tumors. These results are consistent with a model of tumorigenesis in which the development or progression of cancer involves the loss or inactivation of a gene or several genes that normally act to suppress tumorigenesis. One such gene may be located on 9p; this gene may be closely linked to the IFN genes. Nevertheless, loss of the IFN genes, when it occurs, may play an additional role in the progression of these tumors.

Entities:  

Mesh:

Year:  1992        PMID: 1568221

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma.

Authors:  Amy Haseley; Sean Boone; Jeffrey Wojton; Lianbo Yu; Ji Young Yoo; Jianhua Yu; Kazuhiko Kurozumi; Joseph C Glorioso; Michael A Caligiuri; Balveen Kaur
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

2.  Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancers.

Authors:  T Nobori; K Takabayashi; P Tran; L Orvis; A Batova; A L Yu; D A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

3.  Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations.

Authors:  David M Roy; Logan A Walsh; Alexis Desrichard; Jason T Huse; Wei Wu; JianJiong Gao; Promita Bose; William Lee; Timothy A Chan
Journal:  Cancer Cell       Date:  2016-05-09       Impact factor: 31.743

4.  Breakpoint junctions of chromosome 9p deletions in two human glioma cell lines.

Authors:  H M Pomykala; S K Bohlander; P L Broeker; O I Olopade; M O Díaz
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

Review 5.  Progress against cancer.

Authors:  S Broder; J E Karp
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

6.  CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.

Authors:  H Miettinen; J Kononen; P Sallinen; H Alho; P Helen; H Helin; H Kalimo; L Paljärvi; J Isola; H Haapasalo
Journal:  J Neurooncol       Date:  1999-02       Impact factor: 4.130

7.  Patterns of epidermal growth factor receptor amplification in malignant gliomas.

Authors:  G Sauter; T Maeda; F M Waldman; R L Davis; B G Feuerstein
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

Review 8.  Hepatocarcinogenesis in rodents and humans.

Authors:  T Kitagawa; K Miyasaka; H Kanda; H Yasui; O Hino
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 9.  The host STING pathway at the interface of cancer and immunity.

Authors:  Leticia Corrales; Sarah M McWhirter; Thomas W Dubensky; Thomas F Gajewski
Journal:  J Clin Invest       Date:  2016-07-01       Impact factor: 14.808

Review 10.  Molecular cytogenetic quantitation of gains and losses of genetic material from human gliomas.

Authors:  B G Feuerstein; G Mohapatra
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.